SCHEMBL26326669

SCHEMBL26326669

OC(c1ccc(-c2ccccc2)cc1)c1ccc2ccccc2c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.55
SLC6A2 P23975 8/20 0.47
SLC6A4 P31645 8/20 0.47
SLC6A3 Q01959 8/20 0.47
KCNH2 Q12809 5/20 0.47
CYP2D6 P10635 2/20 0.47
CYP3A4 P08684 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ATM Q13315 1/20 0.47
ESR1 P03372 3/20 0.47
ESR2 Q92731 3/20 0.47
CHEK2 O96017 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477557 0.90 UGT2B7 (0.61) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL477559 0.90 UGT2B7 (0.61) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL30161628 0.90 UGT2B7 (0.61) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL600527 0.88 UGT2B7 (0.68) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL30033673 0.88 UGT2B7 (0.68) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL12405817 0.84 UGT2B7 (0.53) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL3585861 0.83 CA12 (0.59) SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4
SCHEMBL4504963 0.81 CA1 (0.62) SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4
SCHEMBL26326655 0.81 UGT2B7 (0.55) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL26326654 0.81 UGT2B7 (0.60) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271988-A1 METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2023-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271988-A1 METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE HPD, TALDO1, OGG1 UGT2B7 300/4885SLC6A2 4398/4885SLC6A4 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.